摘要
In the present report,we review the technical guidelines and principles on impurity research and control for antibiotics established by various agencies,including the International Conference of Harmonization(ICH),the US Food and Drug Administration(FDA),the European Medicines Agency(EMA) and the China Food and Drug Administration(CFDA).Progresses with the US Pharmacopoeia(USP),the European Pharmacopoeia(EP) and the Chinese Pharmacopoeia(ChP) to control impurities in antibiotics are also presented.Next,our discussion is focused on analyzing the CFDA's requirements on impurity research and control for antibiotics,and the implementation of ICH,FDA and other technical guidelines for generic drugs impurity control in China.Existing problems are further reviewed,in order to improve the overall process for the control of antibiotic
In the present report, we review the technical guidelines and principles on impurity research and control for antibiotics established by various agencies, including the International Conference of Harmonization （ICH）, the US Food and Drug Administration （FDA）, the European Medicines Agency （EMA） and the China Food and Drug Administration （CFDA）. Progresses with the US Pharmacopoeia （USP）, the European Pharmacopoeia （EP） and the Chinese Pharmacopoeia （ChP） to control impurities in antibiotics are also presented. Next, our discussion is focused on analyzing the CFDA＇s requirements on impurity research and control for antibiotics, and the implementation of ICH, FDA and other technical guidelines for generic drugs impt^ty control in China, Existing problems are further reviewed, in order to improve the overall process for the control of antibiotic purity
